Evaluation of safety for flibanserin

Area of Science:

• Pharmacology
• Women's Health
• Sexual Dysfunction

Background:

• Hypoactive sexual desire disorder (HSDD) is the most common sexual dysfunction in women.
• Previously, HSDD was managed using off-label treatments.
• Flibanserin is the first FDA-approved medication specifically for HSDD in premenopausal women.

Purpose of the Study:

• To review the pharmacokinetics, mechanism of action, and safety of flibanserin.
• To focus on adverse events like sedation and hypotension, and drug interactions.
• To provide expert opinion on flibanserin's role in HSDD treatment.

Main Methods:

• Review of peer-reviewed publications.
• Inclusion of internal data from the manufacturer.
• Analysis of clinical trial safety data.

Main Results:

• Flibanserin is well-tolerated and effective in treating HSDD.
• It helps decrease distress and restore sexual desire.
• Key safety considerations include sedation, hypotension, and interactions with alcohol and antidepressants.

Conclusions:

• Flibanserin is an effective treatment for HSDD, improving patient distress and desire.
• Simplifying risk mitigation and enhancing education can increase prescribing.
• Long-term pharmacovigilance is crucial as treatment duration can be extensive.